Deep Learning–Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer
The benefit of anti-EGFR therapy in mCRC is confined to patients with a high MBR. Automated sarcopenia assessment holds promise for personalized treatment intensification in mCRC.
Authors
- Amin Dada (ORCID: https://orcid.org/0000-0003-4016-7799)
- Arndt Stahler (ORCID: https://orcid.org/0000-0003-1041-0137)
- Jens Kleesiek (ORCID: https://orcid.org/0000-0001-8686-0682)
- Fabian Hörst (ORCID: https://orcid.org/0000-0002-8906-7644)
- René Hosch (ORCID: https://orcid.org/0000-0003-1760-2342)
- Martin Schüler (ORCID: https://orcid.org/0000-0002-2166-3394)
- Dominik Paul Modest (ORCID: https://orcid.org/0000-0002-6853-0599)
- Philipp Keyl (ORCID: https://orcid.org/0000-0002-5472-4683)
- Julius Keyl (ORCID: https://orcid.org/0000-0002-5617-091X)
- Lothar Müller (ORCID: https://orcid.org/0000-0001-9252-4650)
- Felix Nensa
- Jan Egger
- J. Haubold
- Stefan Kasper
- Jannis Straus
- Sylvia Hartmann
- Sebastian Stintzing
- Stefan Fruehauf
- Alexej Ballhausen
- Tanja Trarbach
- Annabel H. S. Alig
- Annika Kurreck
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Humboldt-Universität zu Berlin (DE)
- National Center for Tumor Diseases (DE)
- St. Marien Hospital (DE)
- Essen University Hospital (DE)
- Praxis für Hämatologie und Onkologie (DE)
- West German Heart and Vascular Center Essen (DE)
- Institute for Gerontological Research (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3080
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 0.00